97 results
8-K
EX-14.1
ADAP
Adaptimmune Therapeutics Plc
24 Jul 17
Amendments to the Registrant's Code of Ethics, or Waiver of a Provision of the Code of Ethics
12:00am
to compromise, an employee’s ability to make objective and fair business decisions.
It is the responsibility of employees to use good judgment in this area … and approval procedures.
The Company’s senior financial officers and other employees working in the finance department have a special responsibility
CORRESP
ADAP
Adaptimmune Therapeutics Plc
18 Oct 18
Correspondence with SEC
12:00am
responsibility for all development, manufacturing and commercialization activities for the NY-ESO SPEAR T-cell program including progression of the NY-ESO … to disclosures on page 15 of the Form 10-Q, which contains the following disclosure, “The IND for the NY-ESO program and the responsibility for the NY
10-K
2016 FY
EX-10.16
ADAP
Adaptimmune Therapeutics Plc
13 Mar 17
Annual report
12:00am
overall responsibility for monitoring the
*** Portions of this page have been omitted pursuant to a request for Confidential Treatment and filed separately … operate as to matters within its responsibility by unanimous vote. ***
. If the JSC is unable to achieve a unanimous vote within *** of any matter being
8-K
EX-99.1
mmnush
1 Oct 19
Adaptimmune Announces Appointment of Michael Garone as Interim Chief Financial Officer
8:14am
8-K
EX-99.1
0itbd7 jp2
24 Jul 18
GSK and Adaptimmune Complete Transition of NY-ESO SPEAR T-cell Therapy Program to GSK
7:36am
8-K
0v074 erm33cwqh9abfe
24 Jul 18
GSK and Adaptimmune Complete Transition of NY-ESO SPEAR T-cell Therapy Program to GSK
7:36am
8-K
jbzm4o
7 Sep 21
Adaptimmune Enters into a Strategic Collaboration with Genentech to Research, Develop, and Commercialize Cancer-targeted Allogeneic T-cell Therapies
7:08am
8-K
z6epjxx ix
11 Apr 23
Adaptimmune and GSK Have Agreed Terms for Transfer of PRAME and NY-ESO Target Programs back to Adaptimmune
8:08am
S-3ASR
EX-5.2
kzybgpxu
10 Aug 20
Automatic shelf registration
5:01pm
8-K
q8ny t16id4c60vb9e
1 Oct 19
Adaptimmune Announces Appointment of Michael Garone as Interim Chief Financial Officer
8:14am
8-K
EX-10.1
p88n 6si7xuu4xqjv0ie
27 Aug 19
Entry into a Material Definitive Agreement
8:39am
DRS
EX-10.2
rk5w6u8c
5 Feb 15
Draft registration statement
12:00am
20-F
EX-4.13
b1k4 53sjltcq
13 Oct 15
Annual report (foreign)
12:00am